Regulatory approval

Published by the Health Canada. Approved

IMFINZI (durvalumab) in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adult patients with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.

This is written in the approval document.

Citation

AstraZeneca Canada Inc. Imfinzi (durvalumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00083579.PDF. Revised February 2026. Accessed April 2025.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HC (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Tremelimumab

Contributions

Date	Contributor	Description
2024-10-30	Van Allen lab	Initial access of FDA approvals